Allergan Inc. (AGN): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Allergan ( AGN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.4%. By the end of trading, Allergan rose $1.05 (1.1%) to $92.63 on average volume. Throughout the day, 2.1 million shares of Allergan exchanged hands as compared to its average daily volume of 2.1 million shares. The stock ranged in a price between $92.34-$93.99 after having opened the day at $92.71 as compared to the previous trading day's close of $91.58. Other companies within the Drugs industry that increased today were: Synta Pharmaceuticals ( SNTA), up 23.5%, Prima Biomed Ltd. ADR ( PBMD), up 13%, Novavax ( NVAX), up 10.7%, and Coronado Biosciences ( CNDO), up 9.4%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $27.72 billion and is part of the health care sector. The company has a P/E ratio of 27, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 5% year to date as of the close of trading on Friday. Currently there are 15 analysts that rate Allergan a buy, no analysts rate it a sell, and nine rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%